PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Highlights the firm's ability to meet near-term obligations and cover interest expenses. For conservative value investors, strong liquidity and coverage metrics are critical to avoid distress or forced dilution.
1.75
0.75–0.9x TRAW's 2.09. Bill Ackman might push for more working capital or better cash management.
1.75
0.75–0.9x TRAW's 2.09. Bill Ackman would recommend finding ways to boost near-cash assets or reduce short-term liabilities.
1.75
Similar ratio to TRAW's 1.78. Walter Schloss would see both following standard liquidity practices.
-32.85
Negative interest coverage while TRAW shows 0.00. Joel Greenblatt would look for earnings improvements and debt restructuring catalysts.
No Data
No Data available this quarter, please select a different quarter.